Plain-English translation of NCT02773849 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial examined , a new treatment delivered directly into the bladder through a catheter. The medication works by introducing a gene that tells your bladder cells to produce a natural immune-boosting protein called interferon alpha2b. This approach was designed to help fight bladder cancer that has stopped responding to the standard BCG treatment.
Some patients with high-grade bladder cancer do not respond well to the standard BCG treatment, and they need new options to avoid surgery to remove their bladder. This medication was being tested to see if it could help these patients control their cancer without losing their bladder.
Participants received the medication through a catheter inserted into the bladder during office visits. The treatment involved intravesical (inside the bladder) administration of the gene therapy, which was designed to stimulate immune cells to fight the cancer. Participants were monitored throughout the study to track how well the treatment worked and to watch for any side effects.
AI-generated summary from trial data · Oct 11, 2026 · Not medical advice
United States